{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T04:00:45Z","timestamp":1780977645645,"version":"3.54.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023544","name":"National Taiwan University Hospital Hsin-Chu Branch Hsin-Chu Hospital","doi-asserted-by":"publisher","award":["112-HCH036"],"award-info":[{"award-number":["112-HCH036"]}],"id":[{"id":"10.13039\/501100023544","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jbo.2026.100756","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T01:15:16Z","timestamp":1774487716000},"page":"100756","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Is strict use of denosumab or zoledronate Beneficial to patients with bone metastatic Disease?"],"prefix":"10.1016","volume":"58","author":[{"given":"Ching-Wei","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-En","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Kuan","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Hsin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shau-Huai","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-Chang","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20 Pt 2","key":"10.1016\/j.jbo.2026.100756_b0005","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.jbo.2026.100756_b0010","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat. Rev."},{"issue":"8","key":"10.1016\/j.jbo.2026.100756_b0015","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","article-title":"Pathologic fractures correlate with reduced survival in patients with malignant bone disease","volume":"110","author":"Saad","year":"2007","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.jbo.2026.100756_b0020","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"35","key":"10.1016\/j.jbo.2026.100756_b0025","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.jbo.2026.100756_b0030","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/ijcp.12022","article-title":"Denosumab: mechanism of action and clinical outcomes","volume":"66","author":"Hanley","year":"2012","journal-title":"Int. J. Clin. Pract."},{"issue":"12","key":"10.1016\/j.jbo.2026.100756_b0035","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO Clinical Practice guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann. Oncol."},{"issue":"15","key":"10.1016\/j.jbo.2026.100756_b0040","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1200\/JCO.19.03148","article-title":"Bone Health and Bone-Targeted Therapies for Prostate Cancer: ASCO Endorsement of a Cancer Care Ontario Guideline","volume":"38","author":"Saylor","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"35","key":"10.1016\/j.jbo.2026.100756_b0045","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.2017.75.4614","article-title":"Role of Bone-Modifying Agents in Metastatic Breast Cancer: an American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update","volume":"35","author":"Van Poznak","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.jbo.2026.100756_b0050","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(13)70174-8","article-title":"Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial","volume":"14","author":"Amadori","year":"2013","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.jbo.2026.100756_b0055","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal events in patients with Bone Metastases: a Randomized Clinical Trial","volume":"317","author":"Himelstein","year":"2017","journal-title":"JAMA"},{"issue":"9768","key":"10.1016\/j.jbo.2026.100756_b0060","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"issue":"28","key":"10.1016\/j.jbo.2026.100756_b0065","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1200\/JCO.2007.11.8604","article-title":"Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases","volume":"25","author":"Lipton","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.jbo.2026.100756_b0070","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju319","article-title":"The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early-stage breast cancer","volume":"106","author":"Hershman","year":"2014","journal-title":"J. Natl Cancer Inst."},{"issue":"6","key":"10.1016\/j.jbo.2026.100756_b0075","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.clinthera.2012.04.008","article-title":"Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer","volume":"34","author":"Snedecor","year":"2012","journal-title":"Clin. Ther."},{"issue":"6","key":"10.1016\/j.jbo.2026.100756_b0080","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1111\/odi.14887","article-title":"Italian position paper (SIPMO-SICMF) on medication-related osteonecrosis of the jaw (MRONJ)","volume":"30","author":"Bedogni","year":"2024","journal-title":"Oral Dis."},{"issue":"7","key":"10.1016\/j.jbo.2026.100756_b0085","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamaoncol.2016.6316","article-title":"Continued Treatment effect of Zoledronic Acid Dosing every 12 vs 4 Weeks in Women with Breast Cancer Metastatic to Bone: the OPTIMIZE-2 Randomized Clinical Trial","volume":"3","author":"Hortobagyi","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.jbo.2026.100756_b0090","article-title":"Revised Strengthening the Reporting of Cohort, Cross-Sectional and Case-Control Studies in Surgery (STROCSS) Guideline: an Update for the Age of Artificial Intelligence. Premier Journal of","volume":"2","author":"Riaz","year":"2025","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.jbo.2026.100756_b0095","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1302\/2046-3758.139.BJR-2023-0372.R1","article-title":"Clinical, oncological, and prognostic differences of patients with subsequent skeletal-related events in bone metastases","volume":"13","author":"Hsieh","year":"2024","journal-title":"Bone Joint Res."},{"issue":"9","key":"10.1016\/j.jbo.2026.100756_b0100","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1097\/CORR.0000000000003030","article-title":"Are Current Survival Prediction Tools Useful when Treating subsequent Skeletal-related events from Bone Metastases?","volume":"482","author":"Pan","year":"2024","journal-title":"Clin. Orthop. Relat. Res."},{"issue":"5","key":"10.1016\/j.jbo.2026.100756_b0105","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","article-title":"American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update","volume":"80","author":"Ruggiero","year":"2022","journal-title":"J. Oral Maxillofac. Surg."},{"issue":"2","key":"10.1016\/j.jbo.2026.100756_b0110","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/CORR.0000000000001036","article-title":"Thirty-day Postoperative Complications after Surgery for Metastatic Long Bone Disease are Associated with Higher Mortality at 1 Year","volume":"478","author":"Bindels","year":"2020","journal-title":"Clin. Orthop. Relat. Res."},{"issue":"5","key":"10.1016\/j.jbo.2026.100756_b0115","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.jbo.2026.100756_b0120","doi-asserted-by":"crossref","first-page":"8403","DOI":"10.1038\/s41598-023-35308-z","article-title":"Long-term use of denosumab and its association with skeletal-related events and osteonecrosis of the jaw","volume":"13","author":"Fu","year":"2023","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.jbo.2026.100756_b0125","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12051209","article-title":"A Retrospective Observational Study of Risk Factors for Denosumab-Related Osteonecrosis of the Jaw in patients with Bone Metastases from Solid Cancers","volume":"12","author":"Okuma","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jbo.2026.100756_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2021.100388","article-title":"Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer","volume":"30","author":"Clemons","year":"2021","journal-title":"J Bone Oncol."},{"issue":"5","key":"10.1016\/j.jbo.2026.100756_b0135","first-page":"4505","article-title":"Prognosis by cancer type and incidence of zoledronic acid-related osteonecrosis of the jaw: a single-center retrospective study","volume":"30","author":"Hata","year":"2022","journal-title":"Support Care Cancer"}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137426000187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137426000187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T03:35:29Z","timestamp":1780976129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137426000187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":27,"alternative-id":["S2212137426000187"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2026.100756","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is strict use of denosumab or zoledronate Beneficial to patients with bone metastatic Disease?","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2026.100756","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100756"}}